BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) will present at the 2021 Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 p.m. ET. Additionally, they will showcase their presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand starting September 13, 2021, at 7:00 a.m. ET. Investors can access the live audio webcast and replays on BioCryst's website. The company focuses on developing oral medicines for rare diseases and has several products approved or in development, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference (virtual). The H.C. Wainwright presentation will be available on-demand in the Investors section of BioCryst’s website starting at 7:00 a.m. ET on Monday, September 13, 2021.

Links to the live audio webcast of the Wells Fargo presentation and replays of both presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals present at the Wells Fargo Healthcare Conference?

BioCryst Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 p.m. ET.

What is the date for the H.C. Wainwright conference presentation for BCRX?

The H.C. Wainwright conference presentation will be available on-demand starting September 13, 2021, at 7:00 a.m. ET.

Where can I find the live audio webcast for BioCryst Pharmaceuticals' presentations?

The live audio webcast and replays for BioCryst's presentations can be accessed in the Investors section of their website.

What products does BioCryst Pharmaceuticals focus on developing?

BioCryst Pharmaceuticals develops oral medicines for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

What is the significance of ORLADEYO for BioCryst Pharmaceuticals?

ORLADEYO (berotralstat) is a key product for BioCryst, approved in multiple markets for treating rare diseases.